Author(s): Roach M, Bae K, Speight J, Wolkov HB, Rubin P, et al.
Purpose
Radiation Therapy Oncology Group (RTOG) 8610 was the first phase III randomized trial to evaluate neoadjuvant androgen deprivation therapy (ADT) in combination with external-beam radiotherapy (EBRT) in men with locally advanced prostate cancer. This report summarizes long-term follow-up results.
Materials and Methods
Between 1987 and 1991, 456 assessable patients (median age, 70 years) were enrolled. Eligible patients had bulky (5 × 5 cm) tumors (T2-4) with or without pelvic lymph node involvement according to the 1988 American Joint Committee on Cancer TNM staging system. Patients received combined ADT that consisted of goserelin 3.6 mg every 4 weeks and flutamide 250 mg tid for 2 months before and concurrent with EBRT, or they received EBRT alone. Study end points included overall survival (OS), disease-specific mortality (DSM), distant metastasis (DM), disease-free survival (DFS), and biochemical failure (BF).
Referred From: https://jco.ascopubs.org/content/26/4/585
Author(s): Huggins C, Hodges CV
Author(s): Sharifi N, Gulley JL, Dahut WL
Author(s): Byar DP
Author(s): Keating NL, O’Malley AJ, Smith MR
Author(s): Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, et al.
Author(s): Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, et al.
Author(s): Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, et al.
Author(s): Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, et al.
Author(s): Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR
Author(s): van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, et al.
Author(s): Martín-Merino E, Johansson S, Morris T, García Rodríguez LA
Author(s): http://www
Author(s): De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al.
Author(s): Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, et al.
Author(s): Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al.
Author(s): Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, et al.
Author(s): Yap TA, Carden CP, Attard G, de Bono JS
